Anticancer
The Phase III study’s principal investigator said that if Xpovio doesn’t win approval, NCCN Guidelines could enable off-label use, as has occurred with BMS’s Reblozyl.
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.
Scrip spoke with Debiopharm’s Luke Piggott about the Swiss biotech’s interest in synthetic lethality and strategy around development and partnering.
The deal, which is expected to close in the first half of 2026, includes $2bn upfront plus $1bn in milestone related payments.
The China-only result bodes well for Merck’s global studies, with Jefferies analysts convinced Sac-TMT will confirm superiority to TROP2 ADC competitors and more.
The drugmaker announced that its Phase II trial of atirmociclib, a CDK4 inhibitor, succeeded in patients who had progressed on CDK4/6 inhibitors and had better tolerability than the earlier class.
The company announced Phase I data for varsetatug masetecan in metastatic colorectal cancer, where it sees a significant and largely untapped market.
The biotech stopped a Phase III trial combining Merck’s Keytruda with eftilagimod alfa in first-line non-small cell lung cancer due to futility.
Six late-stage data readouts are expected from BioNTech this year, with a potential first US oncology approval by 2027 – but before that, it needs to find a new CEO and chief medical officer.
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
Co-founders Ugur Sahin and Özlem Türeci will depart BioNTech to work on a new mRNA spin-out company, but the announcement has left investors uncertain about the German firm’s future
The CELMoD combined with Kyprolis/dexamethasone showed superior PFS, bringing another combination to the second-line disease setting.
Ipsen will withdraw its anticancer, Tazverik, worldwide after its SYMPHONY‑1 trial revealed cases of secondary hematologic malignancy.
Roche’s Phase III persevERA trial of giredestrant plus palbociclib in first-line ER-positive advanced breast cancer has missed its progression-free survival endpoint.
For $2.5bn, the deal will bring Servier a pediatric glioma drug to sell alongside its own Voranigo, and an early-stage clinical pipeline in oncology.
With J&J’s CAR-T Carvykti also approved for second-line disease, an oncologist told Scrip multiple factors will determine who gets which therapy option.
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.